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Background: Inhaled lipopolysaccharide (LPS) induces a dose-dependent, acute neutrophilic response in the
airways of healthy volunteers that can be quantified in induced sputum. Chemokines, such as CXCL1 and CXCL8,
play an important role in neutrophilic inflammation in the lung through the activation of CXCR2 and small molecule
antagonists of these receptors have now been developed. We investigated the effect of AZD8309, a CXCR2
antagonist, compared with placebo on LPS-induced inflammation measured in sputum of healthy volunteers.
Methods: Twenty healthy subjects were randomized in a double-blind placebo-controlled, cross-over study.
AZD8309 (300 mg) or placebo was dosed twice daily orally for 3 days prior to challenge with inhaled LPS and
induced sputum was collected 6 h later.
Results: Treatment with AZD8309 showed a mean 77% reduction in total sputum cells (p < 0.001) and 79%
reduction in sputum neutrophils (p < 0.05) compared with placebo after LPS challenge. There was also a reduction
in neutrophil elastase activity (p < 0.05) and CXCL1 (p < 0.05) and trends for reductions in sputum macrophages
(47%), leukotriene B4 (39%) and CXCL8 (52%).
Conclusions: AZD8309 inhibited LPS-induced inflammation measured in induced sputum of normal volunteers,
indicating that this treatment may be useful in the treatment of neutrophilic diseases of the airways, such as COPD,
severe asthma and cystic fibrosis.
Trial registration: NCT00860821.
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Several chronic inflammatory diseases of the lung, in-
cluding chronic obstructive pulmonary disease (COPD),
cystic fibrosis (CF), severe asthma, acute respiratory dis-
tress syndrome and bronchiolitis obliterans syndrome,
are characterised by a predominantly neutrophilic pat-
tern of inflammation, which is relatively resistant to the
anti-inflammatory effects of corticosteroids, making
them difficult to manage in clinical practice. Several new
anti-inflammatory treatments currently in development
for these diseases such as phosphodiesterase(PDE)-4
and p38 mitogen activated protein (MAP) kinase inhibi-
tors, target neutrophilic inflammation, but their clinical* Correspondence: Brian.Leaker@qasmc.com
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reproduction in any medium, provided the ordevelopment has been hampered by dose-limiting side
effects after oral administration [1,2]. Neutrophilic in-
flammation in the lungs is driven by the release of
chemotactic factors secreted by structural cells within
the lung, such as epithelial and airway smooth muscle
cells, and by resident inflammatory cells, such as macro-
phages and recruited neutrophils. The major neutrophil
chemoattractants are CXC chemokines, including
CXCL1 (GRO-α), CXCL5 (ENA78) and CXCL8 (inter-
leukin-8), all of which are increased in concentration in
bronchoalveolar lavage of patients with COPD, severe
asthma and CF [3-9]. These neutrophil chemokines acti-
vate a common chemokine receptor CXCR2, which is
expressed on the surface of neutrophils. The tripeptide
PGP, which is generated from extracellular matrix pro-
teins through the action of matrix metalloproteinases, isLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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that activates CXCR2 [10,11]. These chemokines also at-
tract circulating monocytes, which differentiate within
the lung to macrophages that are thought to drive neu-
trophilic inflammation [12]. This suggests that blocking
CXCR2 would be an attractive therapeutic approach to
the treatment of neutrophilic inflammation, since small
molecule inhibitors to these G-protein receptors have
now been developed [13,14].
Several small molecule CXCR2 antagonists have now
been developed for oral administration [13]. Oral adminis-
tration of the CXCR2 antagonists navarixin (SCH527123)
and SB-656933 have previously been shown to inhibit the
increased neutrophils in induced sputum as a result of
ozone challenge in normal volunteers [15,16]. Ozone chal-
lenge is difficult as it involves prolonged administration of
ozone in specially designed exposure chambers and the
need for subjects to exercise. Inhaled lipopolysaccharide
(LPS, endotoxin) is well established as an inducer of neu-
trophilic inflammation in normal volunteers and is easier
to administer than ozone [17-20]. We therefore investi-
gated whether inhaled LPS challenge could be used to as-
sess the anti-neutrophilic effect of a CXCR2 antagonist
AZD8309 in normal volunteers.
Studies in animals have shown that neutrophilic
inflammation induced by LPS is attenuated in CXCR2-
deficient mice [21] and small molecule CXCR2 anta-
gonists inhibit pulmonary neutrophilic inflammation
induced by inhaled LPS in several animal species [22].
AZD8309 is a potent small molecule reversible CXCR2
antagonist. Recently oral administration of ADZ8309 has
been shown to inhibit neutrophilia induced by endotoxin
instillation into the nose of normal subjects [23]. In the
present double-blind placebo controlled cross-over study
we investigated the effect of orally administered ADZ8309
on pulmonary inflammation induced by inhaled LPS in
healthy subjects, by measuring inflammatory cells and
mediators in induced sputum.Figure 1 Study design. After a screening visit (visit 1) treatment period 1
comprised of visits 4 and 5. Eligible randomized subjects returned to the c
300 mg AZD8309 or placebo at 09:00 hours and were discharged with inst
challenge the following morning (visit 3). Six hours post-completion of the
was a washout period between visits 3 and 4 of at least 21 days. TreatmenMethods
Study design
We used a double-blind, placebo-controlled two-way
crossover design in which healthy adult subjects were re-
cruited in accordance with the Good Clinical Practice
principles outlined by the Declaration of Helsinki. The
study was powered to detect a 50% reduction in sputum
neutrophil counts, with a 80% power at 5% level. 16 sub-
jects were deemed sufficient to complete the study in a
cross-over design to detect a difference between active
drug versus placebo. The study was approved by Brent
Medical Ethics Committee (London) and all subjects
provided written informed consent prior to any study re-
lated procedures. Figure 1 shows the design and se-
quence of the study as a flow chart. The subjects were
non-smokers or ex-smokers for at least 12 months with
a pack year history <10, FEV1 ≥ 80% predicted normal
and FEV1/FVC >70%, normal airway responsiveness to
inhaled methacholine with a PC20 ≥ 16 mg/mL and able
to produce a minimum of 200 μL sputum volume after
sputum induction at screening.
Demographic measurements were recorded on the
first clinical visit (Visit 1 screening). At Visit 2, subjects
were randomized to treatment and dosed with either an
oral suspension of 300 mg AZD8309 or placebo. A sec-
ond dose was taken approximately 12 hours later, and a
similar dosing regimen was repeated the following day.
A fifth dose was taken at the clinic on the morning of
day 3 and subjects were challenged with inhaled LPS
one hour later. Six hours post-LPS inhalation, hypertonic
saline by aerosol was administered to produce an in-
duced sputum sample. A sixth and final dose was ad-
ministered in the clinic 12 hours after the morning dose
to maintain plasma levels.
Blood samples (collected into EDTA) were collected
on day 1 prior to randomization to treatment and at
7 hours post dosing, on the morning of day 3 prior
dosing and at 6 and 24 hours after LPS challenge forwas comprised of visits 2 and 3 and treatment period 2 was
linic (visit 2) 7–21 days following visit 1 and were dosed with either
ructions for continued dosing at home. Subjects returned for LPS
LPS inhalation, subjects produced an induced sputum sample. There
t period 2 was structured the same as treatment period 1.
Table 1 Demographic and baseline characteristics of
subjects
Parameter All subjects (n = 20)
Sex: Male 20
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AZD8309 concentrations. A washout period of at least
21 days was mandatory before subjects returned to begin
dosing with the second treatment period, which was
structured as the previous visit. A follow-up visit took
place after completion of the final treatment and
comprised a final physical examination and a laboratory
screen.
A dose of 300 mg AZD8309 was used as this dose re-
sulted in maintaining plasma concentrations of AZD8309
at approximately 3 times the IC50 for the CXCR2 receptor
at 12 hour post dosing. The vehicle (and placebo treat-
ment) was hydroxypropyl-methylcellulose, meglumine,
hydroxypropyl-β-cyclodextrin in water.
LPS challenge
1 mg lyophilized LPS (E. coli 026:B6, Sigma Chemical
Company, Poole, UK) was used within 2 hours of recon-
stitution in sterile, isotonic saline. The subject inhaled 5
breaths of 0.50 mg/mL LPS (30 μg) from a breath-
activated Mefar MB3 dosimeter (12 μL per actuation) as
previously described [20].
Sputum induction and processing
Subjects were given increasing concentrations of hyper-
tonic saline (3%, 4% and 5%) for 5 minute periods using
a nebulizer (Medix Ltd, UK). Sputum was collected into
a 50 mL universal container for each 5 min period and
processed within 120 min of collection. Sputum was
processed using dithiothreitol (DTT) at final concentra-
tion of 0.1% in PBS according to the published protocol
[18,19]. The resulting supernatant was stored at −70°C
until analysis.
Induced sputum analysis
Cell pellets were resuspended in 1–5 mL of PBSA (phos-
phate buffered saline plus 0.1% bovine serum albumin).
Viability assessment and total cell count were performed
by the use of trypan blue exclusion staining and a
hemocytometer. Samples were diluted in PBSA to give
2 × 105 viable non-squamous cells per mL and centri-
fuged onto cytospin slides for 3 minutes at 450 rpm. Dif-
ferential counts were expressed as percentage of total cell
counts from Diff-Quik stained cytospin samples (n = 400).
Sputum supernatant samples were analyzed for CXCL1,
CXCL8 and leukotriene (LT) B4 using commercially avail-
able ELISA kits, according to the manufacturer’s guide-
lines (R & D; GE Healthcare, UK). Neutrophil elastase
(NE) activity was determined by an end-point read kinetic
assay run in a 96-well plate format. Samples were incu-
bated with N-methoxysuccinyl-Ala-Ala-Pro-Val-7-amino-
4-methylcoumarin, (Calbiochem, Nottingham UK), which
is cleaved by NE yielding a fluorescent product, 7-amino-
methyl-coumarin. Results were reported as fluorescenceunits and there was no lower limit of quantification
applied.
Statistical analysis
The primary efficacy variable was the neutrophil count
in sputum. This was analyzed using a multiplicative 2-
period crossover ANOVA: the logarithm of the count
was modelled additively with factors treatment, period
and patient. The exponential log of the mean treatment
difference and its confidence interval was used to com-
pare the ratio of geometric means of the count, for
AZD8309 to placebo. The treatment p-value was also
computed non-parametrically using Wilcoxon test (the
treatment difference was compared between the two
randomization sequences). Other sputum variables
(macrophage count, relative cell counts as well as im-
munological mediators) were analyzed in the same way.
Results
Subject demographics
Twenty subjects were randomized to treatment at Visit
2 and 16 completed the study. Of the 20 patients ran-
domized all were males, with a mean age of 26 (range
19–44) years. Sixteen were Caucasian, 3 were black and
1 was Asian. The demographic and baseline characteris-
tics of study subjects are summarized in Table 1. Four
subjects failed to complete the study: 1 subject withdrew
consent, 1 patient in the placebo group withdrew from
the study due to a migraine, 1 subject was withdrawn
because they had screened for another clinical trial at
another unit, and another subject was withdrawn be-
cause they were found to have been over-volunteering
for clinical studies. Of the four subjects who withdrew
from the study, two of them received the LPS challenge
(both on placebo treatment) and all of them received at
least one dose of study drug.
Pharmacokinetic analysis of blood samples taken
post dosing showed that all subjects achieved plasma
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3 × IC50 to antagonize the CXCR2 receptor.
In one subject, there was insufficient sputum pellet to
generate a cytospin for a differential count and on three
occasions there was insufficient sputum supernatant to
be able to do a paired analysis of CXCL1 levels.
Sputum inflammatory cells
Sputum induction and collection were carried out at
Visit 1 to assess whether the subject could produce suffi-
cient volumes, and then again in each treatment period
6 hours post-LPS challenge. Table 2 shows the geometric
means of the total cell counts for all leukocytes, neutro-
phils and macrophages in these sputum samples. There
were only small numbers of eosinophils and lymphocytes
(which were not analyzed further), while most of the
cells were macrophages or neutrophils (Table 2).
Figure 2 shows the effects of treatment on total leuko-
cytes, neutrophils and macrophages in sputum. The total
leukocyte count was reduced by a mean of 77% (P <
0.001) after AZD8309 therapy compared to placebo
levels. There was a mean 79% decrease in the neutrophil
numbers after treatment with AZD8309 compared with
placebo (P = 0.027). Macrophages were reduced by ap-
proximately 50% compared to placebo but this did not
reach statistical significance.
Inflammatory mediators
Figure 3 and Table 3 show the treatment effects on inflam-
matory mediators in induced sputum after LPS challenge.
All were reduced in concentration after treatment with
AZD8309 compared to placebo. There was a mean 52%
reduction in CXCL8 after AZD8309 group compared to
placebo, although this did not reach statistical significance
(P = 0.1), 35% reduction in NE (P = 0.012), 25% lower con-
centrations of CXCL1 (P = 0.044) and 39% lower concen-
trations of LTB4 (p = 0.075). Significance values were
similar for ANOVA and Wilcoxon tests, although a non-
parametric test showed borderline significance effect on
CXCL8 rather than a non-significant result.
Circulating blood leukocytes and mediators
Neutrophil counts in blood were observed to be lower
(on average 29%) when subjects received AZD8309Table 2 Cell count numbers in sputum after LPS challenge in
Cell type (x106/g) N Geometric mean
AZD8309 CV (%)
Total cells 16 5.5 804
Neutrophils 15 3.7 1595
Macrophages 15 1.9 354
P = value by ANOVA; P# = value by Wilcoxon test.
There is only n = 15 for the neutrophil and macrophage numbers because it was no
cytopsin preparations.compared to placebo at 7 hours after dosing on day 1
(mean values: 2.71 × 109/L (± 1.15 S.D.) at 0 hours and
3.04 ×109/L (± 0.85 S.D.) at 7 hours on placebo versus
2.77 × 109/L (± 0.80 S.D.) at 0 hours and 2.03 × 109/L (±
0.89 S.D.) at 7 hours on AZD8309). However, on chal-
lenge with LPS there was no statistically significant dif-
ference between treatment with AZD8309 compared to
placebo on blood neutrophil numbers at 6 hours post
challenge (8.15 × 109/L (± 1.95 S.D.) on placebo; 5.23 ×
109/L (± 1.89 S.D.) on AZD8309, see Figure 4). Blood
neutrophil counts had returned to baseline values by
follow-up (Data not shown).
C-reactive protein (CRP) and IL-6 levels were also
measured in blood at 0, 2, 6 and 25 hours post LPS chal-
lenge. In the placebo-treated group, IL-6 levels were
highest at 6 hours after LPS challenge (1.20 ± 0.84 SD
pg/mL) at 0 hours rising to 34.44 (± 25.94 SD) pg/mL
and CRP levels were highest at 24 hours post LPS chal-
lenge (0.32 ± 0.03 SD mg/l) at 0 hours rising to 6.45 (±
0.27 SD mg/l) at 24 hours). There was no effect of
AZD8309 on blood levels of either IL-6 or CRP.
Lung function
Spirometry was measured at baseline (1 hour before LPS
inhalation) and at 5, 10, 30 min and 1, 2, 3, 4, 5, and
6 hours after inhaled LPS. FEV1 changes within the first
hour post-LPS challenge were similar for placebo and
AZD8309, but there appeared to be a more rapid recov-
ery towards baseline in the subsequent time. Whilst
the difference in effect was small it did reach statistical
significance; the average FEV1 over the 6 hours post
LPS challenge was 4.28 L versus 4.23 L (P < 0.05) for
AZD8309 versus placebo treatment respectively. A time
course of FEV1 changes for each treatment group is
shown in Figure 5.
Adverse effects
A table of the adverse events after first dose of treatment
are shown in Table 4. All adverse effects have been
counted once in the period in which they commenced.
In general adverse effects were balanced across the treat-
ments. The most frequently reported adverse effects
were pyrexia and headache. A total of 44 adverse events
were of mild intensity and 3 (all on placebo) were ofeach treatment group
P P#
Placebo CV (%)
24 252 <0.001 0.003
17 252 0.027 0.028
3.6 523 0.15 0.11
t possible to get a cell differential count from one of the sputum
Figure 2 Effect of AZD8309 on cell counts in sputum post LPS challenge. Total cell counts (top left plot) were performed by trypan blue
exclusion with a hemocytometer. Differential cell counts for neutrophils (top right plot) and macrophages (bottom centre plot) were performed
with cytospin preparations. Bars show the mean values of 15–16 patients. Open bars represent placebo and solid bars AZD8309. Results are
expressed as geometric mean. CVs are shown in Table 2. Statistics by ANOVA, ** = P < 0.001 and * = P < 0.05.
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events in this study.
One subject on placebo treatment was discontinued
from the study drug due to adverse events. On Day 3 of
treatment the subject experienced a migraine (moderate
intensity), nausea (mild intensity) and postural dizziness
(mild intensity). The subject discontinued treatment the
same day.Figure 3 Effect of AZ8309 on mediator concentrations in sputum sup
LPS. There was a reduction in concentrations of CXCL8 (top left plot), CXCL
and leukotriene B4 (LTB4) (Bottom right plot); mean values of 13–16 patien
Results are expressed as geometric mean. CVs are shown in Table 3. StatistAn increase in body temperature was seen from a
mean of 35.9°C pre-dose to 36.9°C at 8 h post-LPS chal-
lenge. This had dropped back to 36.3°C at 24 h post-LPS
challenge. There were no differences between AZD8309
and placebo in these findings.
There were no differences between the treatment
groups in heart rate, systolic or diastolic blood pressure,
and no findings of clinical concern in 12-lead ECG.ernatant. Sputum samples were collected 6 hours post challenge with
1 (top right plot), neutrophil elastase activity (NEA) (bottom left plot)
ts are shown. Open bars represent placebo and solid bars AZD8309.
ics by ANOVA, * = P < 0.05.
Table 3 Soluble mediator concentrations in sputum supernatants after LPS challenge in each treatment group
Mediator N Arithmetic mean Geometric mean P P#
AZD8309 S.D. Placebo S.D. AZD8309 CV (%) Placebo CV (%)
CXCL8 (pg/mL) 16 1373.8 2076.3 2708.2 2880.9 668 251 1404 262 0.1 0.046
CXCL1 (pg/mL) 13 3700.7 5027.0 3934.7 3453.5 2722 75 3622 73 0.044 0.024
LTB4 (ng/mL) 16 0.676 0.530 1.181 0.934 0.54 78 0.87 103 0.075 0.14
NEA (fluor units) 16 3438.8 362.3 6419.4 5793.8 3422 10 5227 66 0.012 0.005
S.D. = standard deviation. P = value by ANOVA; P# = value by Wilcoxon test.
LTB4: leukotriene B4; NEA: neutrophil elastase activity.
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over time, with the exception of leukocytes and neutro-
phils where decreases of approximately 1×109/L during
the AZD8309 treatment period were seen for both mea-
sures. Both parameters returned to baseline values by
the follow-up visit.
Discussion
In the present study, the in vivo pharmacology of a po-
tent CXCR2 antagonist AZD8309 was evaluated in
healthy human subjects using inhalation of LPS, a
method which closely replicates key components of the
inflammatory response associated with COPD, severe
asthma and CF. The main findings of this study are that
following LPS challenge, AZD8309 markedly reduced
total leukocyte numbers and neutrophil numbers in spu-
tum and reduced sputum concentrations of CXCL1,
CXCL8, LTB4 and NE. Furthermore, there were noFigure 4 Effect of AZD8309 on circulating blood neutrophils
pre and post challenge with lipopolysaccharide. Blood
neutrophils numbers were measured at predose (t = 0) and at
7 hours post dosing on day 1 and at trough (t = 0) and at 1, 3, 7, 12
and 25 hours post dosing on day 3. The solid black circles show the
effects on placebo treatment and the open grey circles show effects
after treatment with AZD8309. The arrow indicates the point at
which subjects were challenged with LPS on day 3. Each point is
presented as mean with s.e.m.serious adverse events to an LPS challenge of 30 μg or
dosing with study drug, indicating that this is a useful
and convenient way to initially evaluate the effect of
anti-neutrophilic drugs, such as CXCR2 antagonists.
Short-term treatment with AZD8309 300 mg b.i.d. was
well tolerated with no findings of clinical concern. A po-
tentially interesting additional finding was the observa-
tion that AZD8309 administration significantly increased
the recovery in FEV1 after the small bronchoconstrictor
effect of LPS challenge.
Our primary outcome variable of sputum neutrophils
revealed approximately 80% reduction in subjects receiv-
ing AZD8309 compared to placebo. The increase in neu-
trophils in sputum obtained in the placebo group was
as expected, based on dose–response data previouslyFigure 5 Effect of AZD8309 on FEV1 after inhaled
lipopolysaccharide (LPS). There was a similar peak fall in FEV1 at
1 h after challenge, then a more rapid recovery after AZD8309
compared to placebo, with a significant reduction in area under the
curve (P < 0.05). The average values for the coefficient of variances
were 14.4% and 15% for AZD8309 and placebo respectively. Mean
values of 16 patients are shown.
Table 4 Summary of most common adverse events (AE)
after dosing in each treatment limb
AZD8309 (n = 18) Placebo (n = 19)
Number of subjects with DAE 0 1 (5%)
Total AEs 19 28
Number of subjects with AEs (%) 14 (61%) 10 (53%)
AEs by preferred term n = 18 n = 18
pyrexia 5 (28%) 3 (17%)
headache 2 (11%) 4 (22%)
dizziness 0 3 (17%)
nasal congestion 2 (11%) 3 (17%)
diarrhea 3 (17%) 1 (6%)
rhinitis 0 2 (11%)
pharyngolaryngeal pain 0 2 (11%)
The AEs listed are for all subjects who received at least one dose of study
drug and occurred in more than one subject. DAE = Discontinuation due to
adverse event.
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mediators and markers of neutrophil activation
[18,19,24].
The result of the primary variable, together with the
fact that sputum biomarkers (CXCL1, CXCL8, NE and
LTB4) that are markers of neutrophil activation, were
observed to be lower in subjects receiving AZD8309,
suggests that these effects are mediated through CXCR2.
The effect on inflammatory mediators may not mediated
directly through CXCR2 but reflect the reduction in
numbers of activated neutrophils in the airway, since
these cells release CXCL8, LTB4 and NE. Overall, the re-
sults obtained in this study clearly show that AZD8309
has a positive effect in attenuating the inflammatory re-
sponse induced by LPS inhalation, and the fact that all
subjects achieved trough plasma concentrations of
AZD8309 above the pharmacologically active 3 × IC50
concentration required to antagonize the CXCR2 recep-
tor for the duration of the study gives confidence that
the effects seen were mediated via the expected pharma-
cological mechanism.
AZD8309 also antagonises the CCR2b receptor but it
is 10-fold less potent than at CXCR2 so that even at
maximal plasma concentrations achieved in our study
there would be little if any antagonism of CCR2b. CCR2
are involved in the recruitment of monocytes form the
blood so may be contributory to the increased numbers
of macrophages in COPD patients [25]. The reduction
in sputum macrophages is more likely explained by an
inhibitory effect on CXCR2 which are expressed on cir-
culating monocytes. Our findings are similar to the re-
ported effects of two other CXCR2 antagonists on ozone
challenge in normal subjects [15,16]. A preliminary
study with the CXCR2 antagonist, navarixin (MK7123,
SCH 527123) in patients with COPD showed areduction in sputum neutrophil counts (by approxi-
mately 50%) but no significant change in FEV1 after
three months of treatment [26]. However in a further
study with 6 months dosing, a significant improvement
in FEV1 of up to 168 ml was demonstrated compared
with placebo treated patients [27]. The improvement in
FEV1 was greatest in a sub-group of patients who con-
tinued to smoke and these patients also demonstrated
an increased time to their first moderate/severe exacerba-
tion. A reduction in sputum neutrophil counts was also
shown in a different subset of these patients. The study
also demonstrated a significant dose-related reduction in
systemic neutrophil counts compared with placebo al-
though no difference in infection rates were noted com-
pared with the placebo group (see below). Further Nair
et al. studied SCH527123 [28]. In patients with severe
asthma and after four weeks dosing found a 36% reduction
in sputum neutrophil percentages; but no significant differ-
ences in FEV1, IL-8 release or neutrophil elastase release.
Treatment with AZD8309 also showed a reduction in
circulating neutrophil numbers. This effect has also been
observed in the Phase 1 studies with AZD8309 (unpub-
lished observations) and with navarixin in normal sub-
jects and in COPD patients [15,25]. In the Phase 1
studies the effect on circulating neutrophils was transi-
ent and reversible on stopping dosing. Similarly, in this
study circulating neutrophil numbers returned to pre-
dosing levels as shown in the follow-up visits after stop-
ping treatment with AZD8309. In the present study we
were also able to investigate the effect of AZD8309 on
blood neutrophil numbers after a pro-inflammatory in-
sult using LPS challenge that leads to mobilization of
neutrophils from the bone marrow and a transient in-
crease in circulating neutrophil numbers. AZD8309 had
no effect on the observed increase in blood neutrophils
after LPS challenge suggesting that neutrophils can be
mobilized from the bone marrow regardless of treatment
with a CXCR2 antagonist, and demonstrating that this is
not a compound that causes bone marrow toxicity and
resulting neutropenia. These observations suggest that
the apparent reduction in circulating neutrophils pro-
duced by CXCR2 antagonists is caused by margination
of neutrophils in the pulmonary circulation which can
be rapidly mobilised to the systemic circulation.
AZD8309 300 mg bid was well-tolerated and adverse
events were similar between treatment and placebo
groups. There were no findings of clinical concern, and
no indications that AZD8309 adversely affected lung
function. The transient increase in body temperature ob-
served in both treatment limbs of the study during the
first 8 hours following LPS challenge has previously been
reported with previous LPS challenge studies [17-20,24].
CXCR2 is expressed not only on circulating leukocytes
but also on smooth muscle, submucosal glands and the
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after administration of a potent antagonist [29]. A role
for CXCR2 in neutrophil migration in vivo has been
demonstrated in several animal models [22,30], but less
is known of the in vivo functions of CXCR2 expression
on structural cells or on other populations of inflamma-
tory cells, such as dendritic cells, mast cells and T-
lymphocytes, which also express CXCR2.
An interesting and unexpected finding of this study
was the effect of AZD8309 on lung function following
LPS challenge. As shown in Figure 4, the LPS-induced
initial fall in FEV1 was similar for AZD8309 and placebo.
However there appears to be a faster recovery after
AZD8309 compared to placebo, which may reflect the
effect of reducing neutrophil recruitment into the lungs
and the reduced effects of mediators, such as reactive
oxygen species and other bronchoconstrictor mediators,
released from neutrophils on lung function.
This study details the use of a small number of healthy
subjects in a short and simple challenge procedure
which is reasonably reproducible. In order to validate
our findings further it would be necessary to expand the
trial to accommodate not only larger numbers patients
COPD, severe asthma or CF. Furthermore, acute exacer-
bations of these pulmonary diseases are associated with
increased neutrophilic inflammation in the airways so
CXCR2 antagonists may be effective in preventing and
treating exacerbations [31]. In addition, oral administra-
tion of an anti-inflammatory treatment has a significant
advantage as it may improve access to peripheral airways
compared to inhaled administration and this is particu-
larly important in COPD and severe asthma.
Conclusion
We have demonstrated that a CXCR2 antagonist given
by oral administration can significantly inhibit both the
inflammatory cellular response (neutrophils) and se-
lected mediators in sputum following LPS challenge.
There was a 47% reduction in macrophage numbers, al-
though this did not achieve statistical significance. The
LPS challenge model remains a useful technique for the
evaluation of novel anti-inflammatory drugs in early
stage development.
Our observations support the development of AZD8309
and other CXCR2 antagonists for the treatment of inflam-
matory pulmonary and non-pulmonary diseases charac-
terized by neutrophilia.
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